ClinicalTrials.gg
CompletedNCT01740427Updated Nov 14, 2024Results posted

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

A Phase 3 interventional study of PD-0332991 and Letrozole in Breast Neoplasms, sponsored by Pfizer. Completed at 305 sites in 18 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
666
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.

Enrollment
8th of 111
666 · median 100
Started
2013
with 3 others
Phase 3
20 of 111
4 open now
Registered
8th of 111
by date
Lead sponsor
10 of 111
Pfizer

Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 8th largest by enrollment, is one of 4 that started in 2013, is one of 20 in phase 3, and was the 8th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About palbociclib

palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies testing palbociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The study is designed to compare the clinical benefit following treatment with letrozole in combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.

03

Conditions studied

  • Breast Neoplasms

Keywords

  • breast cancer
  • postmenopausal women
  • estrogen-receptor positive
  • HER2 negative
  • locoregionally recurrent
  • metastatic
  • Palbociclib (PD-0332991)
  • PALOMA-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult women with locoregionally recurrent or disease not amenable to curative therapy.
  • Confirmed diagnosis of ER positive breast cancer
  • No prior systemic anti-cancer therapy for advanced ER+ disease.
  • women
  • as per Response Evaluation Criterion in Solid Tumors [] or bone-only disease
  • [ECOG] 0-2
  • Adequate organ and marrow function
  • Patient must agree to provide tumor tissue

Exclusion criteria

Exclusion Criteria:

  • Confirmed diagnosis of positive disease
  • Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term
  • Known uncontrolled or symptomatic
  • Prior (neo) treatment with letrozole or anastrozole with DFI ≤ 12-months from completion of treatment.
  • Prior treatment with any CDK 4/6 inhibitor.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
666 participants (actual)

Study arms

  • Experimental
    PD-0332991 + Letrozole

    PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).

    Drug: PD-0332991 · Drug: Letrozole

  • Active comparator
    Placebo + Letrozole

    Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).

    Drug: Placebo · Drug: Letrozole

Interventions

  • PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

  • Letrozole, 2.5mg, orally once daily (continuously)

  • DrugPlacebo

    Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment

  • Letrozole, 2.5mg, orally once daily (continuously)

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) as Assessed by the Investigator

    PFS is defined as the time from the date of randomization to the date of the first documentation of objective tumor progression as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) or death due to any cause in the absence of documented PD, whichever occurs first. If tumor progression data include more than 1 date, the first date will be used. PFS (in months) will be calculated as (first event date - randomization date +1)/30.4. Progression is defined using RECIST v1.1, as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions, or the appearance of new lesions.

    Time frame: From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)

Secondary outcomes

  1. Objective Response as Assessed by the Investigator

    Objective Response (OR) defined as overall complete response (CR) or partial response (PR) according to RECIST v1.1. Objective Response Rate (ORR) is defined as proportion of participants with CR or PR relative to all randomized participants with measurable disease at baseline. Participants who do not have on-study radiographic tumor re-evaluation, who received anti-tumor treatment, or who died, progressed/ dropped out for any reason prior to reaching a CR or PR were counted as non-responders in assessment of ORR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.

    Time frame: From randomization until end of treatment (up to approximately 2.5 years)

  2. Objective Response: Participants With Measurable Disease at Baseline as Assessed by the Investigator

    The OR is defined as the overall CR or PR according to the RECIST v1.1. ORR is defined as proportion of participants with CR or PR relative to all randomized participants with measurable disease at baseline. Participants who do not have on-study radiographic tumor re-evaluation, who received anti-tumor treatment, or who died, progressed/ dropped out for any reason prior to reaching a CR or PR were counted as non-responders in the assessment of ORR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.

    Time frame: From randomization until end of treatment (up to approximately 2.5 years)

  3. Duration of Response (DR)

    DR is defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurs first. If tumor progression data included more than 1 date, the first date will be used. DR was calculated as \[the date response ended (i.e. date of PD or death) - first CR or PR date + 1)\]/30.4. DR would only be calculated for the subgroup of participants with an objective tumor response. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions.The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.

    Time frame: From randomization until end of treatment (up to approximately 2.5 years)

  4. Disease Control (DC)/Clinical Benefit Response (CBR)

    DC is defined as overall CR, PR, or stable disease (SD) \>=24 weeks according to RECIST version 1.1. Disease Control Rate (DCR) is defined as participants with CR, PR, or SD \>=24 weeks relative to all randomized participants. Participants who do not have on-study radiographic tumor reevaluation, who received anti-tumor treatment, a best response of SD\>=24 weeks, or who died, progressed, or dropped out for any reason prior to achieving reaching a CR or PR and a best response of SD\>=24 weeks was counted as non-responders in DCR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. SD: neither sufficient shrinkage nor increase to qualify for disease progression.

    Time frame: From randomization until end of treatment (up to approximately 2.5 years)

  5. PFS by Tumor Tissue Biomarkers Status, Including Genes (eg, Copy Numbers of CCND1, CDKN2A), Proteins (eg, Ki67, pRb), and RNA Expression (eg, cdk4, cdk6)

    PFS by biomarker status by Investigator assessment. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Positive is defined as H-Score \>=1 and negative as H-Score \<1. H-Score is calculated as the sum of the % of cells at each level of staining intensity (0, 1+, 2+, and 3+) multiplied by the staining intensity value: H-Score = (% at 0)\*0 + (% at 1+)\*1 + (% at 2+)\*2 + (% at 3+)\*3. H-Score values range from 0 to 300. ER stands for estrogen receptor and Rb stands for retinoblastoma susceptibility gene product.

    Time frame: From randomization until end of treatment (up to approximately 24 Months)

  6. Corrected QT Interval (QTc) Time-Matched Change From Baseline on Cycle 1 Day 14

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and sent to a central laboratory for blinded manual adjudication. The average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Time-matched change from baseline values were reported for QTc analysis population.

    Time frame: Time-matched triplicate ECGs were collected at 0 (predose), 2, 4, 6 and 8 hours on Day 0 and on Cycle1 Day14

  7. Percentage of Participants With Corrected QT Interval (QTc)

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and sent to a central laboratory for blinded manual adjudication. The average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Percentage of participants with post-baseline maximum absolute values and maximum increase from baseline were summarized for the safety analysis population.

    Time frame: For safety monitoring triplicate ECGs were obtained at 0 hour (pre-dose) on Day 1 of Cycle 1, Day 14 of Cycles 1 and Cycle 2, then on Day 1 of Cycles 4, 7, and 10 (ECGs beyond Cycle 10 were performed as clinically indicated)

  8. Observed Plasma Trough Concentration (Ctrough) at Steady-State

    Summary of plasma palbociclib within-participant mean steady-state trough concentrations.

    Time frame: 0 hour (predose) on Day 14 of cycles 1 and 2

  9. Change From Baseline Between Treatment Comparison in Euro Quality of Life (EQ-5D) Index

    The EuroQol EQ-5D is a 6-item instrument designed to assess health status in terms of a single index value or utility score. It contains 5 descriptors of current health state (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with each dimension having 3 levels of function (1=no problem, 2=some problem, and 3=extreme problem). The scores on the 5 descriptors are summarized to create a single summary score. An overall utility score is calculated based on these domains, with a range score from 0 (worse health scenario) to a maximum of 1.0 (best health scenario).

    Time frame: From Baseline up to 2.5 years

  10. Change From Baseline Between Treatment Comparison in Functional Assessment of Cancer Therapy-Breast (FACT-B)

    FACT is a modular approach to assess participant health-related quality of life using a 'core' set of questions (FACT-G) as well as a cancer site-specific module. The FACT-G is a 27-item compilation of general questions divided into 4 domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. The FACT-B consisted of the FACT-G (27-item) and a breast-specific module: a 10-item instrument designed to assess participant concerns relating to breast cancer. For all questions, participants were asked to respond to a five-level scale where 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. FACT-B total score = Physical Well-Being + Social/Family Well-Being + Emotional Well-Being + Functional Well-Being + Breast Cancer Subscale. As each of the items ranges from 0-4, the range of possible scores is 0-144, with 0 being the worst possible score and 144 the best.

    Time frame: From Baseline up to 2.5 years

  11. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs): All Causalities

    An AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. SAE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required hospitalization; resulted in persistent or significant disability or in congenital anomaly/birth defect. TEAE were events that occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Severity was graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0 as Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening and Grade 5 = death related to AE. Discontinuation included permanent, temporary discontinuation and dose reduction due to AEs.

    Time frame: From date of randomization up to 28 days after last dose of study drug (final analysis till study completion, approximately up to 10.51 years)

  12. Overall Survival (OS): Primary Analysis

    OS was defined as the time from date of randomization to date of death due to any cause. Participants without survival data beyond the date of their last follow-up were censored on the last date they were known to be alive. Data for this outcome measure was reported at primary analysis.

    Time frame: From date of randomization until death due to any cause or censored, (assessed up to data cut-off date of 15-Nov-2021, approximately 8.7 years)

  13. Overall Survival (OS): Final Analysis

    OS was defined as the time from date of randomization to date of death due to any cause. Participants without survival data beyond the date of their last follow-up were censored on the last date they were known to be alive. Data for this outcome measure was reported at final analysis.

    Time frame: From date of randomization until death due to any cause or censored (final analysis till study completion, approximately up to 10.51 years)

  14. Survival Probability at 1 Year, 2 Year and 3 Year

    One, two or three-year survival probability was defined as the probability of survival 1 year, 2 or 3 years after the date of randomization. The survival probability was estimated using the Kaplan-Meier method and 2-sided 95% confidence interval (CI) was calculated using the product limit method.

    Time frame: 1, 2 and 3 years after randomization

  15. Number of Participants With Laboratory Abnormalities by Maximum Common Terminology Criteria for Adverse Events (CTCAE) Grade

    Laboratory abnormalities included anemia, hemoglobin increased, neutrophils (absolute), platelets, white blood cells, alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), bilirubin (total), creatinine, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia and hyponatremia. Laboratory abnormalities were graded by CTCAE version (v) 4.0 as Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe and Grade 4 = life-threatening. Categories with at least 1 non-zero data values are reported.

    Time frame: From randomization up to 28 days after last dose of study drug (assessed up to analysis date of 15-Nov-2021, approximately 8.7 years)

07

Results

Posted Apr 26, 2017

Participant flow

A total of 666 participants were randomized at 239 centers in 19 countries.

Participant flow — Overall Study
MilestonePalbociclib Plus LetrozolePlacebo Plus Letrozole
Started444222
Completed00
Not completed444222
Withdrew: Objective progression or relapse286172
Withdrew: Adverse event329
Withdrew: Global deterioration of health status2812
Withdrew: Participant refused continued treatment2715
Withdrew: Unspecified reasons528
Withdrew: Death103
Withdrew: Protocol violation53
Withdrew: Lost to follow-up30
Withdrew: Site terminated by sponsor10

Outcome measures

PrimaryProgression-Free Survival (PFS) as Assessed by the Investigator

PFS is defined as the time from the date of randomization to the date of the first documentation of objective tumor progression as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) or death due to any cause in the absence of documented PD, whichever occurs first. If tumor progression data include more than 1 date, the first date will be used. PFS (in months) will be calculated as (first event date - randomization date +1)/30.4. Progression is defined using RECIST v1.1, as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions, or the appearance of new lesions.

Time frame:
From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)
Reported as:
Median · Months
Progression-Free Survival (PFS) as Assessed by the Investigator
MonthsPalbociclib Plus LetrozolePlacebo Plus Letrozole
Progression-Free Survival (PFS) as Assessed by the Investigator24.8 (22.1 to NA)14.5 (12.9 to 17.1)
Statistical analysis
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Stratified Log Rank · p = <0.000001 (1-sided p-value from the stratified log-rank test.) · Hazard ratio (hr): 0.576 · 95% CI 0.463 to 0.718
SecondaryObjective Response as Assessed by the Investigator

Objective Response (OR) defined as overall complete response (CR) or partial response (PR) according to RECIST v1.1. Objective Response Rate (ORR) is defined as proportion of participants with CR or PR relative to all randomized participants with measurable disease at baseline. Participants who do not have on-study radiographic tumor re-evaluation, who received anti-tumor treatment, or who died, progressed/ dropped out for any reason prior to reaching a CR or PR were counted as non-responders in assessment of ORR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.

Time frame:
From randomization until end of treatment (up to approximately 2.5 years)
Reported as:
Number · Percentage of participants
Objective Response as Assessed by the Investigator
Percentage of participantsPalbociclib Plus LetrozolePlacebo Plus Letrozole
Objective Response as Assessed by the Investigator46.4 (41.7 to 51.2)38.3 (31.9 to 45.0)
Statistical analysis
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Fisher Exact · p = 0.0224 (1-sided p-value is from exact test.) · Odds ratio (or): 1.428 · 95% CI 1.008 to 2.030
SecondaryObjective Response: Participants With Measurable Disease at Baseline as Assessed by the Investigator

The OR is defined as the overall CR or PR according to the RECIST v1.1. ORR is defined as proportion of participants with CR or PR relative to all randomized participants with measurable disease at baseline. Participants who do not have on-study radiographic tumor re-evaluation, who received anti-tumor treatment, or who died, progressed/ dropped out for any reason prior to reaching a CR or PR were counted as non-responders in the assessment of ORR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.

Time frame:
From randomization until end of treatment (up to approximately 2.5 years)
Reported as:
Number · Percentage of participants
Objective Response: Participants With Measurable Disease at Baseline as Assessed by the Investigator
Percentage of participantsPalbociclib Plus LetrozolePlacebo Plus Letrozole
Objective Response: Participants With Measurable Disease at Baseline as Assessed by the Investigator60.7 (55.2 to 65.9)49.1 (41.4 to 56.9)
Statistical analysis
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Fisher Exact · p = 0.0090 (1-sided p-value is from exact test.) · Odds ratio (or): 1.594 · 95% CI 1.080 to 2.347
SecondaryDuration of Response (DR)

DR is defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurs first. If tumor progression data included more than 1 date, the first date will be used. DR was calculated as \[the date response ended (i.e. date of PD or death) - first CR or PR date + 1)\]/30.4. DR would only be calculated for the subgroup of participants with an objective tumor response. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions.The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.

Time frame:
From randomization until end of treatment (up to approximately 2.5 years)
Reported as:
Median · Months
Duration of Response (DR)
MonthsPalbociclib Plus LetrozolePlacebo Plus Letrozole
Duration of Response (DR)20.1 (19.3 to 28.0)16.7 (13.8 to 22.5)
SecondaryDisease Control (DC)/Clinical Benefit Response (CBR)

DC is defined as overall CR, PR, or stable disease (SD) \>=24 weeks according to RECIST version 1.1. Disease Control Rate (DCR) is defined as participants with CR, PR, or SD \>=24 weeks relative to all randomized participants. Participants who do not have on-study radiographic tumor reevaluation, who received anti-tumor treatment, a best response of SD\>=24 weeks, or who died, progressed, or dropped out for any reason prior to achieving reaching a CR or PR and a best response of SD\>=24 weeks was counted as non-responders in DCR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10mm). PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. SD: neither sufficient shrinkage nor increase to qualify for disease progression.

Time frame:
From randomization until end of treatment (up to approximately 2.5 years)
Reported as:
Number · Percentage of participants
Disease Control (DC)/Clinical Benefit Response (CBR)
Percentage of participantsPalbociclib Plus LetrozolePlacebo Plus Letrozole
Disease Control (DC)/Clinical Benefit Response (CBR)85.8 (82.2 to 88.9)71.2 (64.7 to 77.0)
Statistical analysis
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Fisher Exact · p = <0.0001 (1-sided p-value is from exact test.) · Odds ratio (or): 2.451 · 95% CI 1.619 to 3.722
SecondaryPFS by Tumor Tissue Biomarkers Status, Including Genes (eg, Copy Numbers of CCND1, CDKN2A), Proteins (eg, Ki67, pRb), and RNA Expression (eg, cdk4, cdk6)

PFS by biomarker status by Investigator assessment. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Positive is defined as H-Score \>=1 and negative as H-Score \<1. H-Score is calculated as the sum of the % of cells at each level of staining intensity (0, 1+, 2+, and 3+) multiplied by the staining intensity value: H-Score = (% at 0)\*0 + (% at 1+)\*1 + (% at 2+)\*2 + (% at 3+)\*3. H-Score values range from 0 to 300. ER stands for estrogen receptor and Rb stands for retinoblastoma susceptibility gene product.

Time frame:
From randomization until end of treatment (up to approximately 24 Months)
Reported as:
Median · Months
PFS by Tumor Tissue Biomarkers Status, Including Genes (eg, Copy Numbers of CCND1, CDKN2A), Proteins (eg, Ki67, pRb), and RNA Expression (eg, cdk4, cdk6)
MonthsPalbociclib Plus LetrozolePlacebo Plus Letrozole
ER Positive24.9 (22.2 to NA)16.3 (12.9 to 19.1)
ER Negative15.6 (8.3 to 22.0)5.4 (2.7 to 11.1)
Rb Positive24.2 (21.4 to 25.7)13.7 (11.0 to 16.5)
Rb NegativeNA (11.4 to NA)18.5 (2.9 to NA)
Cyclin D1 Positive24.8 (21.5 to 27.6)13.8 (11.3 to 16.8)
Cyclin D1 Negative11.1 (2.2 to 23.9)8.1 (0.4 to NA)
p16 Positive24.8 (21.5 to NA)13.8 (11.1 to 16.8)
p16 Negative16.8 (11.1 to 24.9)13.8 (8.1 to NA)
p16 H-Score<17523.7 (19.6 to 25.7)13.8 (11.2 to 16.8)
p16 H-Score>=17524.2 (11.1 to NA)5.6 (1.5 to 19.1)
Ki67 <=20%27.6 (24.2 to NA)16.8 (13.7 to 22.0)
Ki67 >20%17.5 (13.8 to 22.0)8.4 (5.6 to 13.6)
Statistical analysis
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Unstratified log-rank test · p = <0.0001 · Hazard ratio (hr): 0.571 · 95% CI 0.443 to 0.737Unstratified Cox proportional hazards model was used.
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Unstratified log-rank test · p = 0.0030 · Hazard ratio (hr): 0.405 · 95% CI 0.218 to 0.751Unstratified Cox proportional hazards model was used.
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Unstratified log-rank test · p = <0.0001 · Hazard ratio (hr): 0.531 · 95% CI 0.416 to 0.680Unstratified Cox proportional hazards model was used.
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Unstratified log-rank test · p = 0.3237 · Hazard ratio (hr): 0.675 · 95% CI 0.308 to 1.481Unstratified Cox proportional hazards model was used.
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Unstratified log-rank test · p = <0.0001 · Hazard ratio (hr): 0.555 · 95% CI 0.437 to 0.705Unstratified Cox proportional hazards model was used.
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Unstratified log-rank test · p = 0.9964 · Hazard ratio (hr): 0.997 · 95% CI 0.287 to 3.461Unstratified Cox proportional hazards model was used.
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Unstratified log-rank test · p = <0.0001 · Hazard ratio (hr): 0.518 · 95% CI 0.400 to 0.670Unstratified Cox proportional hazards model was used.
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Unstratified log-rank test · p = 0.3221 · Hazard ratio (hr): 0.731 · 95% CI 0.392 to 1.364Unstratified Cox proportional hazards model was used.
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Unstratified log-rank test · p = <0.0001 · Hazard ratio (hr): 0.581 · 95% CI 0.455 to 0.742Unstratified Cox proportional hazards model was used.
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Unstratified log-rank test · p = 0.0022 · Hazard ratio (hr): 0.255 · 95% CI 0.100 to 0.650Unstratified Cox proportional hazards model was used.
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Unstratified log-rank test · p = 0.0002 · Hazard ratio (hr): 0.530 · 95% CI 0.379 to 0.742Unstratified Cox proportional hazards model was used.
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Unstratified log-rank test · p = 0.0007 · Hazard ratio (hr): 0.569 · 95% CI 0.409 to 0.791Unstratified Cox proportional hazards model was used.
SecondaryCorrected QT Interval (QTc) Time-Matched Change From Baseline on Cycle 1 Day 14

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and sent to a central laboratory for blinded manual adjudication. The average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Time-matched change from baseline values were reported for QTc analysis population.

Time frame:
Time-matched triplicate ECGs were collected at 0 (predose), 2, 4, 6 and 8 hours on Day 0 and on Cycle1 Day14
Reported as:
Least squares mean · msec
Corrected QT Interval (QTc) Time-Matched Change From Baseline on Cycle 1 Day 14
msecPalbociclib Plus LetrozolePlacebo Plus Letrozole
QTcS at 0 hour0.80 (-1.67 to 3.26)2.95 (-0.19 to 6.10)
QTcS at 2 hour3.32 (0.79 to 5.85)1.65 (-1.48 to 4.78)
QTcS at 4 hour2.76 (0.23 to 5.30)1.74 (-1.39 to 4.87)
QTcS at 6 hour4.49 (1.96 to 7.02)0.72 (-2.41 to 3.85)
QTcS at 8 hour0.94 (-1.60 to 3.48)3.14 (0.01 to 6.27)
QTcF at 0 hour1.10 (-1.39 to 3.58)3.06 (-0.11 to 6.23)
QTcF at 2 hour3.68 (1.12 to 6.23)1.73 (-1.43 to 4.88)
QTcF at 4 hour2.86 (0.31 to 5.41)1.54 (-1.62 to 4.70)
QTcF at 6 hour4.57 (2.01 to 7.12)0.71 (-2.44 to 3.87)
QTcF at 8 hour1.21 (-1.36 to 3.77)2.84 (-0.31 to 6.00)
QTcB at 0 hour-0.11 (-2.83 to 2.61)2.78 (-0.69 to 6.25)
QTcB at 2 hour1.46 (-1.34 to 4.25)0.83 (-2.63 to 4.28)
QTcB at 4 hour2.58 (-0.22 to 5.38)2.47 (-0.98 to 5.92)
QTcB at 6 hour4.03 (1.24 to 6.83)0.53 (-2.92 to 3.99)
QTcB at 8 hour-0.17 (-2.98 to 2.64)4.14 (0.69 to 7.59)
SecondaryPercentage of Participants With Corrected QT Interval (QTc)

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and sent to a central laboratory for blinded manual adjudication. The average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Percentage of participants with post-baseline maximum absolute values and maximum increase from baseline were summarized for the safety analysis population.

Time frame:
For safety monitoring triplicate ECGs were obtained at 0 hour (pre-dose) on Day 1 of Cycle 1, Day 14 of Cycles 1 and Cycle 2, then on Day 1 of Cycles 4, 7, and 10 (ECGs beyond Cycle 10 were performed as clinically indicated)
Reported as:
Number · Percentage of participants
Percentage of Participants With Corrected QT Interval (QTc)
Percentage of participantsPalbociclib Plus LetrozolePlacebo Plus Letrozole
Maximum QTcS <450 msec80.585.9
Maximum QTcS 450-<480 msec17.911.8
Maximum QTcS 480-<500 msec1.12.3
Maximum QTcS >=500 msec0.50
Maximum QTcF <450 msec85.989.5
Maximum QTcF 450-<480 msec12.29.5
Maximum QTcF 480-<500 msec1.60.9
Maximum QTcF >=500 msec0.20
Maximum QTcB <450 msec64.969.1
Maximum QTcB 450-<480 msec32.227.3
Maximum QTcB 480-<500 msec2.33.2
Maximum QTcB >=500 msec0.70.5
Maximum QTcS Change <30 msec92.794.5
Maximum QTcS 30<=Change <60 msec6.65.5
Maximum QTcS Change>=60 msec0.70
Maximum QTcF Change <30 msec91.693.6
Maximum QTcF 30<=Change <60 msec7.96.4
Maximum QTcF Change>=60 msec0.50
Maximum QTcB Change <30 msec88.991.4
Maximum QTcB 30<=Change <60 msec10.28.2
Maximum QTcB Change>=60 msec0.90.5
SecondaryObserved Plasma Trough Concentration (Ctrough) at Steady-State

Summary of plasma palbociclib within-participant mean steady-state trough concentrations.

Time frame:
0 hour (predose) on Day 14 of cycles 1 and 2
Reported as:
Geometric mean · Nanogram per milliliter (ng/mL)
Observed Plasma Trough Concentration (Ctrough) at Steady-State
Nanogram per milliliter (ng/mL)Palbociclib Plus Letrozole
Cycle 1 Day 1470.1 ± 59
Cycle 2 Day 1464.2 ± 82
SecondaryChange From Baseline Between Treatment Comparison in Euro Quality of Life (EQ-5D) Index

The EuroQol EQ-5D is a 6-item instrument designed to assess health status in terms of a single index value or utility score. It contains 5 descriptors of current health state (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with each dimension having 3 levels of function (1=no problem, 2=some problem, and 3=extreme problem). The scores on the 5 descriptors are summarized to create a single summary score. An overall utility score is calculated based on these domains, with a range score from 0 (worse health scenario) to a maximum of 1.0 (best health scenario).

Time frame:
From Baseline up to 2.5 years
Reported as:
Mean · Units on a scale
Change From Baseline Between Treatment Comparison in Euro Quality of Life (EQ-5D) Index
Units on a scalePalbociclib Plus LetrozolePlacebo Plus Letrozole
Change From Baseline Between Treatment Comparison in Euro Quality of Life (EQ-5D) Index0.014 (0.00 to 0.03)-0.010 (-0.03 to 0.01)
Statistical analysis
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Mixed Models Analysis · p = 0.0925 · Mean difference (final values): 0.023 · 95% CI -0.004 to 0.051Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
SecondaryChange From Baseline Between Treatment Comparison in Functional Assessment of Cancer Therapy-Breast (FACT-B)

FACT is a modular approach to assess participant health-related quality of life using a 'core' set of questions (FACT-G) as well as a cancer site-specific module. The FACT-G is a 27-item compilation of general questions divided into 4 domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. The FACT-B consisted of the FACT-G (27-item) and a breast-specific module: a 10-item instrument designed to assess participant concerns relating to breast cancer. For all questions, participants were asked to respond to a five-level scale where 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. FACT-B total score = Physical Well-Being + Social/Family Well-Being + Emotional Well-Being + Functional Well-Being + Breast Cancer Subscale. As each of the items ranges from 0-4, the range of possible scores is 0-144, with 0 being the worst possible score and 144 the best.

Time frame:
From Baseline up to 2.5 years
Reported as:
Mean · Units on a scale
Change From Baseline Between Treatment Comparison in Functional Assessment of Cancer Therapy-Breast (FACT-B)
Units on a scalePalbociclib Plus LetrozolePlacebo Plus Letrozole
Change From Baseline Between Treatment Comparison in Functional Assessment of Cancer Therapy-Breast (FACT-B)-0.106 (-1.42 to 1.21)0.219 (-1.68 to 2.12)
Statistical analysis
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Mixed Models Analysis · p = 0.7822 · Mean difference (final values): -0.325 · 95% CI -2.63 to 1.98Analysis based on repeated measures mixed-effects model with an intercept term, treatment, time, treatment-by-time, and baseline as covariate.
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs): All Causalities

An AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. SAE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required hospitalization; resulted in persistent or significant disability or in congenital anomaly/birth defect. TEAE were events that occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Severity was graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0 as Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening and Grade 5 = death related to AE. Discontinuation included permanent, temporary discontinuation and dose reduction due to AEs.

Time frame:
From date of randomization up to 28 days after last dose of study drug (final analysis till study completion, approximately up to 10.51 years)
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs): All Causalities
Percentage of participantsPalbociclib Plus LetrozolePlacebo Plus Letrozole
Participants with AEs99.196.4
Participants with SAEs28.217.1
Participants with Grade 3 or 4 AEs83.130.2
Participants with Grade 5 AEs3.62.3
Permanently discontinued study due to AEs4.12.3
Permanently disc. palbociclib/placebo due to AEs14.46.3
Permanently discontinued letrozole due to AEs9.25.9
Temporarily disc. palbociclib/placebo due to AEs79.717.1
Temporarily discontinued letrozole due to AEs23.011.3
With palbociclib/placebo dose reduction due to AEs41.92.3
SecondaryOverall Survival (OS): Primary Analysis

OS was defined as the time from date of randomization to date of death due to any cause. Participants without survival data beyond the date of their last follow-up were censored on the last date they were known to be alive. Data for this outcome measure was reported at primary analysis.

Time frame:
From date of randomization until death due to any cause or censored, (assessed up to data cut-off date of 15-Nov-2021, approximately 8.7 years)
Reported as:
Median · Months
Overall Survival (OS): Primary Analysis
MonthsPalbociclib Plus LetrozolePlacebo Plus Letrozole
Overall Survival (OS): Primary Analysis53.9 (49.8 to 60.8)51.2 (43.7 to 58.9)
Statistical analysis
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Stratified Log Rank · p = 0.337750 (1-sided p-value from the stratified log-rank test.) · Hazard ratio (hr): 0.956 · 95% CI 0.777 to 1.177
SecondaryOverall Survival (OS): Final Analysis

OS was defined as the time from date of randomization to date of death due to any cause. Participants without survival data beyond the date of their last follow-up were censored on the last date they were known to be alive. Data for this outcome measure was reported at final analysis.

Time frame:
From date of randomization until death due to any cause or censored (final analysis till study completion, approximately up to 10.51 years)
Reported as:
Median · Months
Overall Survival (OS): Final Analysis
MonthsPalbociclib Plus LetrozolePlacebo Plus Letrozole
Overall Survival (OS): Final Analysis53.8 (49.8 to 59.2)49.8 (42.3 to 56.4)
Statistical analysis
  • Palbociclib Plus Letrozole vs Placebo Plus Letrozole · Stratified Log Rank · p = 0.208706 (1-sided p-value from the stratified log-rank test.) · Hazard ratio (hr): 0.921 · 95% CI 0.755 to 1.124
SecondarySurvival Probability at 1 Year, 2 Year and 3 Year

One, two or three-year survival probability was defined as the probability of survival 1 year, 2 or 3 years after the date of randomization. The survival probability was estimated using the Kaplan-Meier method and 2-sided 95% confidence interval (CI) was calculated using the product limit method.

Time frame:
1, 2 and 3 years after randomization
Reported as:
Number · Percent probability
Survival Probability at 1 Year, 2 Year and 3 Year
Percent probabilityPalbociclib Plus LetrozolePlacebo Plus Letrozole
1 year survival probability92.7 (89.8 to 94.7)94.9 (91.0 to 97.2)
2 year survival probability78.4 (74.1 to 82.0)82.5 (76.6 to 87.0)
3 year survival probability69.8 (65.1 to 73.9)65.0 (58.0 to 71.1)
SecondaryNumber of Participants With Laboratory Abnormalities by Maximum Common Terminology Criteria for Adverse Events (CTCAE) Grade

Laboratory abnormalities included anemia, hemoglobin increased, neutrophils (absolute), platelets, white blood cells, alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), bilirubin (total), creatinine, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia and hyponatremia. Laboratory abnormalities were graded by CTCAE version (v) 4.0 as Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe and Grade 4 = life-threatening. Categories with at least 1 non-zero data values are reported.

Time frame:
From randomization up to 28 days after last dose of study drug (assessed up to analysis date of 15-Nov-2021, approximately 8.7 years)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities by Maximum Common Terminology Criteria for Adverse Events (CTCAE) Grade
ParticipantsPalbociclib Plus LetrozolePlacebo Plus Letrozole
Anemia: Grade 1-232890
Anemia: Grade 3306
Hemoglobin Increased: Grade 1-21425
Hemoglobin Increased: Grade 310
Neutrophils (Absolute): Grade 1-210942
Neutrophils (Absolute): Grade 32542
Neutrophils (Absolute): Grade 4601
Platelets: Grade 1-228932
Platelets: Grade 360
Platelets: Grade 410
White Blood Cells: Grade 1-224857
White Blood Cells: Grade 31770
White Blood Cells: Grade 460
ALT: Grade 1-222276
ALT: Grade 3160
ALT: Grade 410
Alkaline Phosphatase: Grade 1-217495
Alkaline Phosphatase: Grade 370
AST: Grade 1-226082
AST: Grade 3232
Bilirubin (Total): Grade 1-23311
Bilirubin (Total): Grade 330
Creatinine: Grade 1-2418201
Creatinine: Grade 380
Creatinine: Grade 420
Hypercalcemia: Grade 1-211154
Hypercalcemia: Grade 312
Hyperkalemia: Grade 1-211851
Hyperkalemia: Grade 361
Hyperkalemia: Grade 420
Hypermagnesemia: Grade 1-27126
Hypermagnesemia: Grade 396
Hypermagnesemia: Grade 420
Hypernatremia: Grade 1-29435
Hypernatremia: Grade 381
Hypoalbuminemia: Grade 1-211842
Hypoalbuminemia: Grade 320
Hypocalcemia: Grade 1-215848
Hypocalcemia: Grade 341
Hypocalcemia: Grade 430
Hypokalemia: Grade 1-210532
Hypokalemia: Grade 3112
Hypomagnesemia: Grade 1-212741
Hypomagnesemia: Grade 310
Hypomagnesemia: Grade 420
Hyponatremia: Grade 1-210744
Hyponatremia: Grade 3114

Adverse events

Collected over From the date of randomization up to 28 days after last dose of study medication (final analysis till study completion, approximately up to 10.51 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Palbociclib Plus Letrozole16/444 (3.6%)125/444 (28.2%)435/444 (98%)
Placebo Plus Letrozole6/222 (2.7%)38/222 (17.1%)209/222 (94.1%)
Most frequent serious events
Showing 10 of 193
Most frequent serious events
EventPalbociclib Plus LetrozolePlacebo Plus Letrozole
PneumoniaInfections and infestations4/4445/222
Febrile neutropeniaBlood and lymphatic system disorders8/4440/222
Urinary tract infectionInfections and infestations6/4440/222
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/4443/222
AnaemiaBlood and lymphatic system disorders5/4440/222
Acute kidney injuryRenal and urinary disorders5/4440/222
Pleural effusionRespiratory, thoracic and mediastinal disorders5/4441/222
VomitingGastrointestinal disorders2/4442/222
Disease progressionGeneral disorders4/4440/222
PyrexiaGeneral disorders4/4440/222
Most frequent other events
Showing 10 of 76
Most frequent other events
EventPalbociclib Plus LetrozolePlacebo Plus Letrozole
NeutropeniaBlood and lymphatic system disorders308/4448/222
ArthralgiaMusculoskeletal and connective tissue disorders187/44489/222
FatigueGeneral disorders183/44465/222
NauseaGastrointestinal disorders169/44459/222
AlopeciaSkin and subcutaneous tissue disorders150/44436/222
Hot flushVascular disorders101/44469/222
DiarrhoeaGastrointestinal disorders136/44451/222
CoughRespiratory, thoracic and mediastinal disorders127/44448/222
AnaemiaBlood and lymphatic system disorders125/44423/222
HeadacheNervous system disorders109/44462/222

Baseline characteristics

The intent-to-treat (ITT) population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or received a different drug from that to which they were randomized.

Age, Continuous
Age, Continuous(Years)Palbociclib Plus LetrozolePlacebo Plus LetrozoleTotal
Mean61.7 ± 10.660.6 ± 11.261.3 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Palbociclib Plus LetrozolePlacebo Plus LetrozoleTotal
Female444222666
Male000
08

Study locations

305 sites
  • Southern California Permanente Medical Group
    Bellflower, California 90706, United States
  • Beverly Hills Cancer Center
    Beverly Hills, California 90211, United States
  • St. Joseph Heritage Healthcare
    Fullerton, California 92835, United States
  • Los Angeles Hematology/Oncology Medical Group
    Glendale, California 91206, United States
  • UCLA Hematology/ Oncology- Irvine
    Irvine, California 92604, United States
  • UCLA Hematology Oncology- Laguna Hills
    Laguna Hills, California 92653, United States
  • Los Angeles Hematology/Oncology Medical Group
    Los Angeles, California 90017, United States
  • Southern California Permanente Medical Group
    Los Angeles, California 90027, United States
  • Translational Research Management
    Los Angeles, California 90045, United States
  • Drug Management Only: UCLA West Medical Pharmacy, Attn: Steven L Wong, Pharm.D.
    Los Angeles, California 90095-1772, United States
  • UCLA West Medical Pharmacy, Attn: Steven L. Wong
    Los Angeles, California 90095-7349, United States
  • UCLA West Medical Pharmacy: Drug Management Only
    Los Angeles, California 90095-7349, United States
  • UCLA West Medical Pharmacy; Drug Management Only
    Los Angeles, California 90095-7349, United States
  • UCLA West Medical Pharmacy
    Los Angeles, California 90095-7349, United States
  • Administrative Address: UCLA Hematology/Oncology
    Los Angeles, California 90095, United States
  • Drug Management Only: TRIO-US Pharmacy UCLA Medical Plaza, Attn: Steven L Wong, Pharm.D.
    Los Angeles, California 90095, United States
  • Regulatory Management Only: TRIO-US Central Administration
    Los Angeles, California 90095, United States
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
  • TRIO-US Central Administration: Regulatory Management Only
    Los Angeles, California 90095, United States
  • TRIO-US Central Administration
    Los Angeles, California 90095, United States
  • UCLA Hematology Oncology
    Los Angeles, California 90095, United States
  • UCLA Hematology/Oncology
    Los Angeles, California 90095, United States
  • UCLA Hematology/ Oncology- Pasadena
    Pasadena, California 91105, United States
  • Torrance Health Association, DBa Torrance Memorial Physician Network
    Redondo Beach, California 90277, United States
  • Southern California Permanente Medical Group
    San Diego, California 92108, United States
  • University of California, San Francisco
    San Francisco, California 94115, United States
  • University of California San Francisco - Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94158, United States
  • San Luis Obispo Oncology and Hematology Health Center/ Pacific Central Coast Health Centers
    San Luis Obispo, California 93401, United States
  • Central Coast Medical Oncology Corporation
    Santa Maria, California 93454, United States
  • UCLA Santa Monica Medical Center and Orthopaedic Hospital
    Santa Monica, California 90404, United States
  • Stanford Women's Cancer Center
    Stanford, California 94304-5826, United States
  • Wellness Oncology & Hematology
    West Hills, California 91307, United States
  • UCLA Hematology/Oncology- Westlake
    Westlake Village, California 91361, United States
  • St. Mary's Hospital Regional Cancer Center
    Grand Junction, Colorado 81501, United States
  • Smilow Cancer Hospital at Yale New Haven
    New Haven, Connecticut 06510, United States
  • Whittingham Cancer Center @ Norwalk Hospital
    Norwalk, Connecticut 06856, United States
  • MedStar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Sylvester at Deerfield Beach
    Deerfield Beach, Florida 33442, United States
  • Memorial Breast Cancer Center at Memorial Regional Hospital
    Hollywood, Florida 33021, United States
  • Memorial Cancer Institute at Memorial Regional Hospital
    Hollywood, Florida 33021, United States
  • Memorial Regional Hospital
    Hollywood, Florida 33021, United States
  • Cancer Specialist of North Florida, Pharmacy
    Jacksonville, Florida 32256, United States
  • Cancer Specialists of North Florida-Southpoint
    Jacksonville, Florida 32256, United States
  • Orlando Health, Inc.
    Orlando, Florida 32806, United States
  • Memorial Breast Cancer Center at Memorial Hospital West
    Pembroke Pines, Florida 33028, United States
  • Memorial Cancer Institute at Memorial Hospital West
    Pembroke Pines, Florida 33028, United States
  • Memorial Hospital West
    Pembroke Pines, Florida 33028, United States
  • Sylvester Comprehensive Cancer Center Plantation
    Plantation, Florida 33324, United States
  • Cancer Specialists of North Florida - St. Augustine
    Saint Augustine, Florida 32086, United States
  • Grady Health System
    Atlanta, Georgia 30303, United States
  • Emory University Hospital Midtown
    Atlanta, Georgia 30308, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Northwest Georgia Oncology Centers, PC
    Marietta, Georgia 30060, United States
  • Kootenai Clinic Cancer Services
    Coeur d'Alene, Idaho 83814, United States
  • Kootenai Clinic Cancer Services
    Post Falls, Idaho 83854, United States
  • The Mark M. Connolly Center for Cancer and Specialty Care
    Chicago, Illinois 60657, United States
  • Carle Foundation Hospital DBA Carle Cancer Center
    Danville, Illinois 61832, United States
  • Carle Foundation Hospital DBA Carle Cancer Center
    Effingham, Illinois 62401, United States
  • Presence Infusion Care- Evanston
    Evanston, Illinois 60202, United States
  • Carle Foundation Hospital DBA Carle Cancer Center
    Mattoon, Illinois 61938, United States
  • Presence Infusion Care- Skokie
    Skokie, Illinois 60077, United States
  • Carle Foundation Hospital DBA Carle Cancer Center
    Urbana, Illinois 61801, United States
  • James Graham Brown Cancer Center and University Hospital
    Louisville, Kentucky 40202, United States
  • James Graham Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • University of Maryland, Greenebaum Cancer Center
    Baltimore, Maryland 21201, United States
  • Walter Reed National Military Medical Center
    Bethesda, Maryland 20889-5600, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109, United States
  • Park Nicollet Frauenshuh Cancer Center
    Saint Louis Park, Minnesota 55426, United States
  • The West Clinic, PC
    Corinth, Mississippi 38834, United States
  • The West Clinic, PC dba West Cancer Centre
    Southaven, Mississippi 38671, United States
  • Mercy Clinic St. Louis Cancer and Breast Institute
    Ballwin, Missouri 63011, United States
  • Mercy Clinic St. Louis Cancer and Breast Institute
    Saint Louis, Missouri 63109, United States
  • Mercy Hospital St. Louis - David C. Pratt Cancer Center
    Saint Louis, Missouri 63141, United States
  • Mercy Hospital St. Louis
    Saint Louis, Missouri 63141, United States
  • Saint Francis Medical Center
    Grand Island, Nebraska 68802, United States
  • Saint Francis Medical Center, Saint Francis Cancer Treatment Center
    Grand Island, Nebraska 68803, United States
  • Saint Francis Medical Center
    Hastings, Nebraska 68901, United States
  • Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89052, United States
  • Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89074-8195, United States
  • Regulatory Office: Comprehensive Cancer Centers of Nevada Research Department
    Las Vegas, Nevada 89119, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89128, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89148, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • CareMount Medical
    Brewster, New York 10509, United States
  • CareMount Medical
    Mount Kisco, New York 10549, United States
  • Northern Westchester Hospital
    Mount Kisco, New York 10549, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Stony Brook University- Cancer Center
    Stony Brook, New York 11794-9447, United States
  • Northwest Cancer Specialists, PC
    Portland, Oregon 97213, United States
  • Kaiser Permanente Northwest Region
    Portland, Oregon 97227, United States
  • Northwest Cancer Specialists, P.C.
    Portland, Oregon 97227, United States
  • OHSU Center for Health and Healing 2
    Portland, Oregon 97239, United States
  • OHSU Center for Health and Healing
    Portland, Oregon 97239, United States
  • OHSU Research Pharmacy Services
    Portland, Oregon 97239, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Tennessee Oncology, PLLC
    Dickson, Tennessee 37055, United States
  • Tennessee Oncology PLLC
    Franklin, Tennessee 37067, United States
  • Tennessee Oncology, PLLC
    Gallatin, Tennessee 37066, United States

Showing the first 100 of 305 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Zhu Z, Turner NC, Loi S, Andre F, Martin M, Dieras V, Gelmon KA, Harbeck N, Zhang C, Cao JQ, Yan Z, Lu DR, Wei P, VanArsdale TL, Rejto PA, Huang X, Rugo HS, Loibl S, Cristofanilli M, Finn RS, Liu Y. Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib. NPJ Precis Oncol. 2022 Aug 16;6(1):56. doi: 10.1038/s41698-022-00297-1. PubMed 35974168 ↗
  • Gelmon K, Walshe JM, Mahtani R, Joy AA, Karuturi M, Neven P, Lu DR, Kim S, Schnell P, Bananis E, Schwartzberg L. Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2. Breast. 2021 Oct;59:321-326. doi: 10.1016/j.breast.2021.07.017. Epub 2021 Jul 28. PubMed 34388698 ↗
  • Iwata H, Umeyama Y, Liu Y, Zhang Z, Schnell P, Mori Y, Fletcher O, Marshall JC, Johnson JG, Wood LS, Toi M, Finn RS, Turner NC, Bartlett CH, Cristofanilli M. Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3. Oncologist. 2021 Jul;26(7):e1143-e1155. doi: 10.1002/onco.13811. Epub 2021 Jun 7. PubMed 33955129 ↗
  • Finn RS, Rugo HS, Gelmon KA, Cristofanilli M, Colleoni M, Loi S, Schnell P, Lu DR, Theall KP, Mori A, Gauthier E, Bananis E, Turner NC, Dieras V. Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. Oncologist. 2021 May;26(5):e749-e755. doi: 10.1002/onco.13684. Epub 2021 Mar 10. PubMed 33486783 ↗
  • Zheng J, Yu Y, Durairaj C, Dieras V, Finn RS, Wang DD. Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib. Target Oncol. 2021 Jan;16(1):69-76. doi: 10.1007/s11523-020-00771-5. PubMed 33211314 ↗
  • Finn RS, Cristofanilli M, Ettl J, Gelmon KA, Colleoni M, Giorgetti C, Gauthier E, Liu Y, Lu DR, Zhang Z, Bartlett CH, Slamon DJ, Turner NC, Rugo HS. Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast Cancer Res Treat. 2020 Nov;184(1):23-35. doi: 10.1007/s10549-020-05782-4. Epub 2020 Aug 11. PubMed 32783178 ↗
  • Huang Bartlett C, Mardekian J, Cotter MJ, Huang X, Zhang Z, Parrinello CM, Bourla AB. Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer. PLoS One. 2020 Apr 21;15(4):e0227256. doi: 10.1371/journal.pone.0227256. eCollection 2020. PubMed 32315295 ↗
  • Ettl J, Im SA, Ro J, Masuda N, Colleoni M, Schnell P, Bananis E, Lu DR, Cristofanilli M, Rugo HS, Finn RS. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Res. 2020 Mar 12;22(1):27. doi: 10.1186/s13058-020-01263-0. PubMed 32164785 ↗
  • Rugo HS, Finn RS, Gelmon K, Joy AA, Harbeck N, Castrellon A, Mukai H, Walshe JM, Mori A, Gauthier E, Lu DR, Bananis E, Martin M, Dieras V. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2. Clin Breast Cancer. 2020 Apr;20(2):e173-e180. doi: 10.1016/j.clbc.2019.08.009. Epub 2019 Sep 5. PubMed 31836434 ↗
  • Dieras V, Harbeck N, Joy AA, Gelmon K, Ettl J, Verma S, Lu DR, Gauthier E, Schnell P, Mori A, Rugo HS, Finn RS. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. Oncologist. 2019 Dec;24(12):1514-1525. doi: 10.1634/theoncologist.2019-0019. Epub 2019 Jun 19. PubMed 31217344 ↗
  • Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. Breast Cancer. 2019 Sep;26(5):637-650. doi: 10.1007/s12282-019-00970-7. Epub 2019 May 24. Erratum In: Breast Cancer. 2019 Sep;26(5):651. doi: 10.1007/s12282-019-00984-1. PubMed 31127500 ↗
  • Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, Iyer S, Mori Y, Mori A, Gauthier E, Finn RS, Toi M. Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. J Glob Oncol. 2019 May;5:1-19. doi: 10.1200/JGO.18.00173. PubMed 31125276 ↗
  • Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, Yamamoto Y, Nishimura R, Sato N, Ohsumi S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Lu DR, Toi M. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. Int J Clin Oncol. 2019 Mar;24(3):274-287. doi: 10.1007/s10147-018-1353-9. Epub 2018 Dec 4. PubMed 30515674 ↗
  • Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W, Iyer S, Schnell P, Bartlett CH, Johnston S. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Cancer. 2018 Sep;101:123-133. doi: 10.1016/j.ejca.2018.05.017. Epub 2018 Jul 25. PubMed 30053671 ↗
  • Dieras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. J Natl Cancer Inst. 2019 Apr 1;111(4):419-430. doi: 10.1093/jnci/djy109. PubMed 30032196 ↗
  • Wedam SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, Tang S, Goldberg KB, Sridhara R, Ibrahim A, Kim G, Kluetz P, McKee A, Pazdur R. US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments. J Clin Oncol. 2018 Apr 20;36(12):1225-1231. doi: 10.1200/JCO.2017.74.6917. Epub 2018 Mar 9. PubMed 29522361 ↗
  • Rugo HS, Dieras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CHUANG, Iyer S, Johnston S, Ettl J, Harbeck N. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018 Apr 1;29(4):888-894. doi: 10.1093/annonc/mdy012. PubMed 29360932 ↗
  • Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Dieras V, Moulder S, Lipatov O, Colleoni M, Cristofanilli M, Lu DR, Mori A, Giorgetti C, Iyer S, Bartlett CH, Gelmon KA. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol. 2018 Mar 1;29(3):669-680. doi: 10.1093/annonc/mdx797. PubMed 29342248 ↗
  • Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Dieras V, Slamon DJ. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016 Nov 17;375(20):1925-1936. doi: 10.1056/NEJMoa1607303. PubMed 27959613 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2013 to primary completion in Feb 2016, 36 months.

Results were first posted in Apr 2017, 1 year 2 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 36 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2012
First posted
Dec 4, 2012
StartActual
Feb 22, 2013
Primary completionActual
Feb 26, 2016
CompletionActual
Nov 9, 2023
Results first posted
Apr 26, 2017
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01740427
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 4, 2012
Start date
Feb 22, 2013
Primary completion
Feb 26, 2016
Completion
Nov 9, 2023
Results posted
Apr 26, 2017
Last update
Nov 14, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palbociclib

Start the discussion